KPTI
Karyopharm Therapeutics Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Karyopharm Therapeutics Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Karyopharm Therapeutics Inc.
0.65
Fund move
Fund move
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | RA Capital ManagementRA Capital Management | $18.7M | 8.41% | 0.00% | |
| 2 | Adage Capital Partners GPAdage Capital Partners GP | $14.9M | 6.67% | −15.78% | |
| 3 | Acorn Capital AdvisorsAcorn Capital | $14.8M | 6.66% | +427.44% | |
| 4 | Goldman Sachs GroupGoldman Sachs | $13.9M | 6.25% | +50.35% | |
| 5 | BlackRockBlackRockindex-like | $13.9M | 6.22% | +479.34% | |
| 6 | Vanguard Capital ManagementVanguardindex-like | $9.4M | 4.21% | +29.64% | |
| 7 | Catalio Capital ManagementCatalio | $9.2M | 4.13% | +4.81% | |
| 8 | Avidity Partners ManagementAvidity Partners | $9.0M | 4.05% | −0.32% | |
| 9 | T. Rowe Price Investment ManagementT. Rowe Price | $7.7M | 3.45% | −49.01% | |
| 10 | Two Sigma InvestmentsTwo Sigma | $6.8M | 3.05% | +359.73% | |
| 11 | Kalehua Capital ManagementKalehua | $6.7M | 3.01% | new | |
| 12 | NEA ManagementNEA | $5.6M | 2.53% | new | |
| 13 | Susquehanna International GroupSusquehanna International | $5.3M | 2.39% | −58.50% | |
| 14 | Geode Capital ManagementGeodeindex-like | $5.2M | 2.33% | +157.71% | |
| 15 | Ghisallo Capital ManagementGhisallo | $4.9M | 2.19% | new | |
| 16 | Soleus Capital ManagementSoleus | $4.3M | 1.93% | 0.00% | |
| 17 | Caption ManagementCaption | $3.7M | 1.66% | −68.00% | |
| 18 | UBS GroupUBS | $3.5M | 1.55% | +82.22% | |
| 19 | Millennium ManagementMillennium | $3.3M | 1.50% | −33.21% | |
| 20 | State StreetState Streetindex-like | $3.2M | 1.43% | +303.74% | |
| 21 | Affinity Asset AdvisorsAffinity Asset | $3.1M | 1.37% | −37.50% | |
| 22 | Brevan Howard Capital ManagementBrevan Howard | $3.0M | 1.36% | +45.89% | |
| 23 | Boxer Capital ManagementBoxer | $3.0M | 1.33% | 0.00% | |
| 24 | Davidson Kempner Capital ManagementDavidson Kempner | $2.9M | 1.32% | 0.00% | |
| 25 | Acadian Asset ManagementAcadian | $2.9M | 1.31% | +20.10% |
99 managers report $222.7M of Karyopharm Therapeutics on form 13F for the quarter ended Jun 30 '26. 25 of them hold 80% of it; RA Capital Management is largest at 8.41%.
Linked news
Expected move
Inputsspot 0.66exp Nov 20ATM strike 0.5ATM straddle 0.42IV 398%